Candel Therapeutics Analyst Ratings
Candel Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/02/2022 | 511.11% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/31/2022 | 566.67% | BMO Capital | $18 → $12 | Maintains | Outperform |
| 11/19/2021 | 900% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 400% | UBS | → $9 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1122.22% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 08/23/2021 | 733.33% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 12/02/2022 | 511.11% | HC Wainwright & Co. | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/31/2022 | 566.67% | BMO Capital | 18 美元 → 12 美元 | 維持 | 跑贏大盤 |
| 11/19/2021 | 900% | BMO Capital | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/23/2021 | 400% | 瑞銀（UBS） | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/23/2021 | 1122.22% | 傑富瑞集團 | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/23/2021 | 733.33% | 瑞士信貸 | → 15 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的目標價格是多少？
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by HC Wainwright & Co. on December 2, 2022. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 511.11% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年12月2日公佈了Candel Therapeutics（納斯達克股票代碼：CADL）的最新目標股價。該分析公司將目標股價設定爲11.00美元，預計CADL將在12個月內上漲至11.11％（可能上漲511.11％）。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的最新分析師評級是多少？
The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by HC Wainwright & Co., and Candel Therapeutics initiated their buy rating.
Candel Therapeutics（納斯達克股票代碼：CADL）的最新分析師評級由HC Wainwright & Co. 提供，Candel Therapeutics啓動了買入評級。
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Candel Therapeutics（CADL）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on December 2, 2022 so you should expect the next rating to be made available sometime around December 2, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Candel Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Candel Therapeutics的最後一次評級是在2022年12月2日提交的，因此您應該預計下一個評級將在2023年12月2日左右公佈。
Is the Analyst Rating Candel Therapeutics (CADL) correct?
分析師對Candel Therapeutics（CADL）的評級是否正確？
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a initiated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $1.80, which is within the analyst's predicted range.
儘管評級是主觀的，而且將發生變化，但Candel Therapeutics（CADL）的最新評級是啓動的，目標股價爲0.00美元至11.00美元。Candel Therapeutics（CADL）目前的交易價格爲1.80美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。